Athira Pharma’s stock price fell 81% as its lead fosgonimeton treatment for Alzheimer’s disease failed its phase II/III LIFT-AD clinical trial. The drug did not meet the trial’s primary or key secondary endpoints. However, chief medical officer Javier San Martin said Athira planned to continue developing fosgonimeton, citing preliminary results from various subgroups.
Louis Vuitton says UK customer data stolen in cyber-attack – The Guardian
Summarize this content to a maximum of 60 words: Louis Vuitton says UK customer data stolen in cyber-attack The Guardian
